HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

New rules mandate that most insurers must now cover the cost. Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of ...

The patent for branded TDF/emtricitabine (Truvada) has expired, allowing multiple manufacturers to offer inexpensive generic versions that contain the same ingredients. Branded TAF/emtricitabine ...

What Truvada is, is a single pill that’s a combination of two antiretroviral drugs that have a long history of being used as part of a broader combination of therapy for the actual treatment of ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

At issue was a battle over patents for Truvada and a newer, upgraded version called Descovy — two highly effective and lucrative medications — as well as the role played by the federal ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Northern Ireland's foremost gay campaign group has accepted a five-figure donation from a pharma corporation which has come ...

Gilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory committee meeting on Wednesday with a mostly-positive verdict from ...

Foster City, California-based Gilead collaborated with the CDC in the mid-2000s to test if Gilead's Truvada could prevent transmission of HIV, the virus that causes AIDS, in addition to treating it.